Methods and compositions for treating or preventing lesions of the respiratory epithelium
This invention features methods of treating lesions of the airway epithelium by local or systemic administration of intestinal trefoil peptides. The intestinal trefoil peptide can be administered either alone or in combination with one or more therapeutic agents.
1 . A method for treating asthma in a mammal, comprising administering to said mammal a composition comprising a therapeutically effective amount of a trefoil peptide, or a biologically active fragment thereof.
2 . The method of claim 1 , wherein said trefoil peptide is intestinal trefoil factor (ITF), spasmolytic polypeptide, or pS2.
3 . The method of claim 1 , wherein said biologically active fragment is a fragment of intestinal trefoil factor (ITF) and is selected from the group consisting of ITF 15-73 , ITF 21-73 , ITF 1-72 , ITF 15-72 , and ITF 21-72 , wherein the bounds of said fragment are delineated according to SEQ ID NO.: 1.
4 . The method of claim 3 , wherein said biologically active fragment is ITF 15-73 .
5 . The method of claim 1 , wherein said administration is by inhalation.
6 . The method of claim 1 , wherein said composition further comprises a second therapeutic agent.
7 . The method of claim 6 , wherein said second therapeutic agent is an anti-inflammatory agent, antimicrobial agent, antihistamine, neurokinin receptor antagonist, leukotriene receptor antagonist, decongestant, cholinergic receptor antagonist, phosphodiesterase inhibitor, or a beta-adrenergic bronchodilator.
8 . The method of claim 7 , wherein said anti-inflammatory agent is a glucocorticoid.
9 . The method of claim 6 , wherein said beta-adrenergic bronchodilator is albuterol, bitolterol, epinephrine, fenoterol, formoterol, isoetharine, isoproterenol, metaproterenol, pirbuterol, procaterol, racepinephrine, salmeterol, or terbutaline.
10 . The method of claim 1 , wherein said biologically active fragment of a trefoil peptide is encoded by an isolated nucleic acid molecule that hybridizes under high stringency conditions to a polynucleotide having the sequence of SEQ ID NO.: 4, SEQ ID NO.: 5, SEQ ID NO.: 6, SEQ ID NO.: 7, SEQ ID NO.: 8, or SEQ ID NO.: 9.
11 . A pharmaceutical composition suitable for inhalation administration for the treatment of asthma in a mammal, wherein said composition comprises a trefoil peptide, or a biologically active fragment thereof, and a pharmaceutically acceptable carrier.
12 . The composition of claim 11 , wherein said trefoil peptide is intestinal trefoil factor (ITF), spasmolytic polypeptide, or pS2.
13 . The composition of claim 11 , wherein said biologically active fragment is ITF 15-73 , ITF 21-73 , ITF 1-72 , ITF 15-72 , or ITF 21-72 .
14 . The composition of claim 11 , wherein said biologically active fragment is ITF 15-73 .
15 . The composition of claim 11 , wherein said composition is an aerosol or a dry powder.
16 . The composition of claim 11 , wherein said composition further comprises a second therapeutic agent.
17 . The composition of claim 16 , wherein said second therapeutic agent is an anti-inflammatory agent, antimicrobial agent, antihistamine, neurokinin receptor antagonist, leukotriene receptor antagonist, decongestant, cholinergic receptor antagonist, phosphodiesterase inhibitor, or a beta-adrenergic bronchodilator.
18 . The composition of claim 17 , wherein said anti-inflammatory agent is a glucocorticoid.
19 . The composition of claim 17 , wherein said beta-adrenergic bronchodilator is albuterol, bitolterol, epinephrine, fenoterol, formoterol, isoetharine, isoproterenol, metaproterenol, pirbuterol, procaterol, racepinephrine, salmeterol, or terbutaline.
20 . The composition of claim 11 , wherein said trefoil peptide is encoded by an isolated nucleic acid sequence that hybridizes under high stringency conditions with the sequence of SEQ ID NO.: 4, SEQ ID NO.: 5, SEQ ID NO.: 6, SEQ ID NO.: 7, SEQ ID NO.: 8, or SEQ ID NO.: 9.